The European Commission announced Monday that it will decide by January 14 whether to approve Swiss pharmaceutical conglomerate Novartis’s plans to merge with UK rival GlaxoSmithKline.
Novartis is set to acquire Glaxo’s oncology product unit in a $14.5 billion acquisition; an additional $1.5 billion would be paid pending results of an ongoing melanoma treatment trial, reports say.
Glaxo, meanwhile, would acquire Novartis’s vaccines operations, without the flu vaccine, for $5.25 billion, as well as potential royalties and milestone payments of up to $1.8 billion.
The Commission is investigating the terms of the transaction and will rule next month on the deal. The announcement comes days after the Commission approved of medical device maker Medtronic’s acquisition of Covidien for $43 billion, though regulators implemented concessions on the deal.
Full content: Today Online
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI